Pipeline
ENABLING BROAD APPLICATIONS FOR RNA TREATMENTS
Replicate is advancing a robust pipeline of srRNA treatments spanning several therapeutic areas. Our pipeline achieves initial clinical proof of concept in infectious disease, demonstrating a best-in-class technology, advances a first-in-class oncology candidate to IND, and demonstrates the potential of the technology with two candidate selections in major therapeutic areas with clear preclinical inflection points.


Program
Indication
Mechanism
of action
of action
Discovery
Preclinical
Phase 1
Vaccines
RBI-4000
Rabies vaccine
Viral glycoprotein
PHASE 1 – COMPLETE
RBI-5000
Infectious mononucleosis
Multiple antigens of
Epstein Barr virus
Epstein Barr virus
Preclinical
RBI-RESP
RSV/hMPV/PIV
Multiple antigens
Discovery
Therapeutics
RBI-8000
Inflammatory/
Auto-immune
Auto-immune
Pan inflammasome
inhibitor
(IL-1/IL-18 inhibitor)
inhibitor
(IL-1/IL-18 inhibitor)
Discovery
RBI-X000
Partnered with Novo Nordisk
Partnered with Novo Nordisk
Diabetes /
Obesity
Obesity
Undisclosed
Discovery
RBI-1000
ER+ breast
cancer
cancer
Endocrine therapy
resistance
resistance
Preclinical
Clinical trial information
Replicate is currently studying RBI-4000 in a Phase 1 clinical trial to evaluate clinical proof of concept, safety, and tolerability in humans. To find out more about the trial and eligibility, visit:

